QuantHealth
Category: AI in Healthcare
An AI-powered platform that simulates clinical trials to accelerate and de-risk drug development for pharmaceutical and biotechnology companies. QuantHealth was founded in 2020. The company is led by Orr Inbar. Based in Tel Aviv, Israel. Team size: 51-200. Total funding raised: $30 million. Latest round: Strategic Investment. Key investors include Sanofi Ventures, Accenture Ventures, Bertelsmann Investments, Pitango HealthTech, Shoni Top Ventures, Nina Capital.
- Founded
- 2020
- Headquarters
- Tel Aviv, Israel
- Team size
- 51-200
- Total funding
- $30 million
Value proposition
To significantly reduce the time, cost, and risk of drug development by using AI to predict clinical trial outcomes with high accuracy, thus addressing the 90% failure rate of drugs in clinical development.
Products and solutions
Clinical Trial Simulator, Large Real-World Drug Model (LRDM v1.0), Katina, QuantHealth Clinical Development OS, Predictive Competitive Positioning
Unique value
QuantHealth's platform creates a 'digital twin' of a clinical trial, simulating thousands of variations to optimize for success. Built on a dataset of over 350 million patients, it can predict trial outcomes with high accuracy.
Target customer
Pharmaceutical and biotechnology companies, specifically their Clinical Development (ClinDev) and Clinical Operations (ClinOps) teams.
Industries served
Pharmaceuticals, Biotechnology, Life Sciences
Technology advantage
Proprietary AI engine and the Large Real-World Drug Model (LRDM v1.0), a foundation model trained on a vast and diverse dataset, enabling highly accurate predictions and simulations for clients.
How they differentiate
QuantHealth differentiates through its AI-powered simulation platform and proprietary LRDM, creating patient 'digital twins' to predict trial outcomes with claimed high accuracy, enabling de-risking and optimization of trial design before live execution.
Main competitors
Unlearn, Owkin, InSilicoTrials
Key partnerships
Sanofi Ventures, Accenture Ventures, Boston Pharmaceuticals
Notable customers
Works with 8 of the top 20 global pharmaceutical companies (specific names largely undisclosed)., Sanofi (via strategic investment from Sanofi Ventures)., Accenture (via strategic investment from Accenture Ventures).
Major milestones
Secured a strategic investment from Sanofi Ventures to accelerate AI-driven clinical trials., Unveiled its Large Real-World Drug Model (LRDM v1.0), a pharmaco-clinical foundation model for life sciences., Successfully simulated over 350 clinical trials, achieving up to 90% accuracy., Closed a $15M Series A funding round and later extended it with investments from Accenture and others., Established partnerships with major pharmaceutical companies and healthcare data firms like Atropos Health., Achieved 8x sales growth and announced record financial returns across life sciences engagements (March 2026)., Bolstered executive leadership team with new SVP of Sales and Head of Marketing & Communications (March 2026)., Launched Predictive Competitive Positioning capabilities to optimize for market success (May 2026).
Growth metrics
As of early 2026, QuantHealth reports simulating over 600 clinical trials with 85% endpoint prediction accuracy, achieving 8x sales growth, and delivering $215M+ in financial returns for pharmaceutical clients across 23+ therapeutic areas.
Market positioning
Positioned as a specialized AI solution provider focused on optimizing clinical trial design and predicting outcomes for large pharma and biotech firms, aiming to reduce failure rates and costs in drug development.
Geographic focus
Headquartered in Tel Aviv, Israel, with a significant presence in the United States (Cambridge, MA) and a global business focus targeting North America and Europe.
Patents and IP
Information not publicly available.
About Orr Inbar
Co-founder and CEO of Pando, an HR tech startup. Previously an investor at Viola Growth and a consultant at Bain & Company.
Official website: https://quanthealth.ai/